Benefits of denosumab in treating bone metastases
A&S Science Previous     Next

Benefits of denosumab in treating bone metastases

Carole Farrell Nurse clinician, The Christie NHS Foundation Trust, Manchester

While bisphosphonates are widely used to treat bone disease, many patients experience significant problems. Carole Farrell outlines a new therapy, given as a subcutaneous injection, which can be administered in an outpatient clinic

This article discusses normal bone remodelling and explains how this changes when cancer cells invade the bone. Denosumab is a new agent for the treatment of bone metastases that has a different mode of action from the bisphosphonates used traditionally to treat metastatic bone disease. The article goes on to outline the potential benefits of denosumab use for patients, health professionals and service delivery.

Cancer Nursing Practice. 11, 9,14-18. doi: 10.7748/cnp2012.11.11.9.14.c9406

Correspondence

Carole.farrell@christie.nhs.uk

Conflict of interest

This article was supported by Amgen

Peer review

This article has been subject to double blind peer review

You need a subscription to read the full article